NR0B1 and metabolic dysfunction-associated steatotic liver disease: The utilization of Resmetirom leads to a significant reduction in fat, attributed to the activation of THR-β, a nuclear hormone receptor crucial for regulating impaired metabolic pathways in NAFLD and NASH24.